IMBdx

Our Solution

Early detection of cancer.

Presentations

게시물 목록
NO	YEAR	SUBJECT	JOURNAL NAME	LINK
13	2025	Perioperative Tumor-Informed ctDNA Monitoring for Minimal Residual Disease in Triple-Negative and HER2-Positive Breast Cancer Patients Perioperative Tumor-Informed ctDNA Monitoring for Minimal Residual Disease in Triple-Negative and HER2-Positive Breast Cancer Patients American Assoiation for Cancer Research (AACR) MRD monitoring Perioperative Tumor-Informed ctDNA Monitoring for Minimal Residual Disease in Triple-Negative and HER2-Positive Breast Cancer Patients	American Assoiation for Cancer Research (AACR)
12	2025	Analytical validation of CancerDetectTM RUO assay: A minimal residual disease detection test that integrates tumor-informed and tumor-agnostic approaches with large-scale mutation profiling Analytical validation of CancerDetectTM RUO assay: A minimal residual disease detection test that integrates tumor-informed and tumor-agnostic approaches with large-scale mutation profiling American Assoiation for Cancer Research (AACR) MRD monitoring Analytical validation of CancerDetectTM RUO assay: A minimal residual disease detection test that integrates tumor-informed and tumor-agnostic approaches with large-scale mutation profiling	American Assoiation for Cancer Research (AACR)
11	2025	Multi-cancer detection: Is it appropriate for early detection of pancreatic cancer with plasma WGS - Multi-cancer detection: Is it appropriate for early detection of pancreatic cancer with plasma WGS	International Pancreatobiliary Meeting (IPBM)
10	2025	Detection of mutations in Homologous Recombination Repair (HRR) pathway genes using liquid biopsy in metastatic, castration-resistant prostate cancer (mCRPC) patients without tumor tissue availability Background: Blood samples (20ml of whole blood) were collected fr\|om 760 mCRPC patients in 10 Asian countries. Samples were collected once for each patient, regardless of treatment type or cycles as long as the patients were followed up for their mCRPC. All patients included were confirmed fr\|om each participating site to have no tissue available for genomic analysis. Blood samples were analyzed using a next-generation sequencing (NGS) based ctDNA assay, covering 15 genes in the HRR pathway (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L). Results: ctDNA testing for HRR gene mutations offers a practical tool for therapy selection in mCRPC patients. This non-invasive approach enables testing for patients who were not eligible for evaluation by tissue-based methods and can expand access to adequate targeted therapies. Detection of mutations in Homologous Recombination Repair (HRR) pathway genes using liquid biopsy in metastatic, castration-resistant prostate cancer (mCRPC) patients without tumor tissue availability LINK VIEW	ASCO GU	LINK _VIEW
9	2024	Enhancing Lung Nodule Discrimination with a Novel cfDNA Test The Cancer Signature Ensemble (CSE) Approach Background Lung cancer is the leading cause of cancer-related deaths worldwide, with over 40% of patients diagnosed at stage IV, mainly due to difficulties in early detection. Although low-dose CT (LDCT) screening assists in early diagnosis, its high false-positive rate demands more accurate and minimally invasive biomarkers. In LDCT screening, about 5% of cases exhibit lung nodules with a 5% or higher risk of malignancy (Lung-RADS category 4); however, most are benign, with actual lung cancers representing only 0.6% of the total screened population. A diagnostic test is essential to avoid unnecessary invasive examinations and identify individuals at higher lung cancer risk. Other liquid biopsy approaches using restricted range of biomarkers have diagnostic limitations for early-stage cancers. Enhancing Lung Nodule Discrimination with a Novel cfDNA Test The Cancer Signature Ensemble (CSE) Approach	European Association for Cancer Research (EACR)